In many families the heart attack stories are about the men: an uncle, a grandfather, a father taken too young. The guidelines tell a different story about women, and it starts in the years around the menopause.
Heart health
Heart disease is often thought of as a man's illness. For South Asian women in midlife, the guidelines say otherwise. Here is what they say about the risk, the checks worth asking for, and where HRT fits.
The words and the guidance
- English
- Heart health
- Also searched as
- cardiovascular health, heart disease, cardiovascular disease
- Urdu
- دل کی صحت
- Roman Urdu
- dil ki sehat
- The Pakistan Menopause Society's 2026 recommendations put the average age of menopause in Pakistan at between 45 and 49, lower than among white European women (Introduction).
- The British Menopause Society says South Asian women show a higher rate of heart risk factors during the menopause transition, naming metabolic syndrome, insulin resistance and diabetes, weight around the middle, and high blood pressure.
- The PMS recommendations ask doctors to use the menopause visit for prevention: checking blood pressure, BMI, blood sugar, cholesterol and tobacco use (Table 1).
- NICE NG23 says HRT should not be offered to prevent heart disease, either a first episode or a repeat one, and points doctors to its separate guideline on lowering heart risk (1.6.4).
What it is
Heart health here means the heart and the blood vessels together: heart attacks, angina and stroke, and the things that build towards them, such as high blood pressure, cholesterol and diabetes.
The European Menopause and Andropause Society (EMAS) says heart disease in women is still too little studied, too often missed and too rarely treated.
Why it happens
The Pakistan Menopause Society puts the average age of menopause in Pakistan at between 45 and 49, lower than among white European women.
EMAS adds risks that only women carry: high blood pressure, diabetes or eclampsia in pregnancy, and a premature menopause.
The PMS recommendations add a caution: doctors should avoid implying that every midlife illness comes from falling estrogen, because age, lifestyle and other conditions all play their part (Table 1).
What the guidance lists
The PMS recommendations treat the menopause visit as a chance for prevention. They list:
- Checks: blood pressure, BMI and ideally waist size, with a fasting blood sugar or HbA1c and a cholesterol test according to age, risk and affordability (Tables 2 and 4).
- Questions: a family history of heart disease and blood clots, and her own history of diabetes, blood pressure, smoking and stroke (Table 2).
- Movement: regular physical activity, which the recommendations say has evidence for protecting the heart (4.2.2). See aerobic exercise.
- Food: they name sweetened drinks and colas as driving weight around the middle and metabolic risk, and encourage dals, channa, saag, methi and whole grains (Table 5). Women's Health Concern says refined starches such as white rice and white bread can be part of a healthy diet and need not be avoided, though more wholegrain is the aim.
- Tobacco: stopping cigarettes, naswar and shisha, which they say lowers heart disease risk. They note that shisha is often seen as less harmful, and ask doctors to address it anyway (Table 7). See smoking, naswar and shisha.
What the guidelines say about treatment
On HRT and the heart, NICE NG23 says two things.
First, HRT is not a heart medicine: recommendation 1.6.4 says it should not be offered to prevent heart disease, and points doctors to separate guidance on lowering heart risk.
Second, for women taking HRT for their symptoms, NICE's table of benefits and risks says: "Coronary heart disease risk does not increase with combined HRT". The same table says: "Mortality from cardiovascular disease does not increase with combined HRT." For stroke, the same table says the risk depends partly on whether the estrogen is taken as a tablet or through the skin.
The PMS recommendations describe what they call the timing hypothesis: the idea that the balance of benefit and risk is most favourable when HRT is started before 60 or within ten years of the menopause, particularly for the heart (section 5). The Menopause Society, rating the evidence as strong, says the same about timing, and that women who start later face higher absolute risks of heart disease, clots and stroke, so starting after 60 needs careful weighing of a woman's own benefits and risks.
For women who already have heart disease, the British Menopause Society's guidance for clinicians says HRT is usually considered high risk and that non-hormonal treatment comes first. It also says a history of heart disease may not be an absolute bar to HRT, and that the choice should be shared, weighing her symptoms against her risk. The PMS recommendations list high heart risk among the reasons to refer a woman to a menopause specialist (3.4).
When to see a doctor
If your blood pressure, blood sugar or cholesterol have not been checked for a few years, ask at your next appointment.
Some symptoms cannot wait for an appointment. The PMS recommendations list chest pain, swelling in one leg, sudden shortness of breath, neurological symptoms, or a severe new headache as red flags that need evaluation or referral (2.3). Do not wait for a routine appointment with any of these.
Heart palpitations that come with chest pain or sudden breathlessness fall under those same red flags.
Questions to ask your doctor
- Given my family history, what is my risk of heart disease, and has it been worked out?
- Can we check my blood pressure, blood sugar and cholesterol today, or when should I have them done?
- I had high blood pressure or diabetes in pregnancy. Does that change my heart risk now?
- Does my heart risk change whether HRT is an option for me, and which type?
- If I already have a heart condition, can you refer me to someone with menopause expertise?
Faith and family
Family history is the one test you can do at home. Ask your mother and aunts about heart attacks, strokes, diabetes and blood pressure tablets, and take the answers to your doctor, who the PMS recommendations ask to record it (Table 2).
In Ramadan, women on blood pressure, cholesterol or diabetes medicines often ask how to time them around sehri and iftar, or whether they should fast at all. The question about the fast belongs with a qualified scholar; the question about the medicine belongs with whoever prescribes it, before Ramadan starts.
Track it
- Roshara's symptom score rates 27 symptoms in a few minutes, with no account. The total is something to take to your appointment. Take the symptom score
- Where am I? names the stage you might be in. Six questions. Take Where am I?
- Log it day by day in the tracker, with what came just before. It needs a free account. Open the tracker
Common questions
- Does the menopause cause heart disease?
- Not on its own. The British Menopause Society says heart risk factors become more common in South Asian women during the menopause transition, and the Pakistan Menopause Society warns against blaming every midlife illness on falling estrogen (Table 1). (Source: Pakistan Menopause Society, Good Clinical Practice Recommendations for Menopause Care in Pakistan (JSOGP 16(2), 28 April 2026))
- Will HRT protect my heart?
- NICE NG23 says HRT should not be offered for the prevention of heart disease (1.6.4). Its table of benefits and risks also says "Coronary heart disease risk does not increase with combined HRT", which is a different question from protection. (Source: NICE NG23, Menopause: identification and management (last updated 15 April 2026))
- Can I take HRT if I already have heart disease?
- It depends on the condition. The British Menopause Society's guidance for clinicians says a history of heart disease may not rule HRT out completely, and that the decision should be shared between a woman and her doctor. (Source: British Menopause Society, Tool for Clinicians: Management of menopause for women with cardiovascular disease (published October 2024))
Sources
- NICE NG23, Menopause: identification and management (last updated 15 April 2026)Section: 1.6.2, Table 1 (coronary heart disease); 1.6.4 Cardiovascular disease prevention · Opened 1 October 2026© NICE 2026 Menopause: identification and management. Available from www.nice.org.uk/guidance/ng23 All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
- Pakistan Menopause Society, Good Clinical Practice Recommendations for Menopause Care in Pakistan (JSOGP 16(2), 28 April 2026)Section: Introduction; Tables 1, 2, 4, 5 and 7; 2.3; 3.4; 4.2 · Opened 1 October 2026
- British Menopause Society, Tool for Clinicians: Menopause in ethnic minority women (published June 2023, review was due June 2026)Section: South Asian women · Opened 1 October 2026
- British Menopause Society, Tool for Clinicians: Management of menopause for women with cardiovascular disease (published October 2024)Section: Whole tool · Opened 1 October 2026
- Women's Health Concern, Nutrition in menopause (factsheet, reviewed September 2026)Section: Should I avoid starchy carbohydrates? · Opened 10 October 2026
- European Menopause and Andropause Society, Menopause Essentials 2026: Heart disease and stroke (July 2026)Section: Risk factors for coronary heart disease; closing note · Opened 15 October 2026
- The Menopause Society (then The North American Menopause Society), The 2022 hormone therapy position statement, Menopause 2022;29(7):767-794Section: Cardiovascular disease and all-cause mortality: key points; Duration of use, initiation after age 60 years, and discontinuation: key points · Opened 15 October 2026